Currently, Antibody-drug conjugates (ADCs) such as Enfortumab Vedotin targeting Nectin-4, Disitamab Vedotin targeting HER2, have shown promising effect in the treatment of solid tumors, including BLCA [30, 31]. This evidence concerns the gene ERBB2 and bladder transitional cell carcinoma.